Abstract
This chapter provides a brief overview of the methods of percutaneous thermal ablation including high-intensity focused ultrasound, interstitial laser, microwave, cryo and radiofrequency currently in use, followed by a discussion of the potential use of these modalities in patients with colorectal cancer. The most common indication for thermal ablation in this group of patients is the treatment of metastatic disease to the liver. Ideal candidates for this therapy will have disease limited to the liver, with no more than three lesions, all less than 3 cm in diameter. Indications may be expanded to treat patients with a single larger lesion, or in other instances where the objective is palliation rather than “cure. ” Technical issues that make some lesions treatable and other similar lesions not are outlined. The use of ablative therapies in other areas of the body such as lung and bone are also discussed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Goldberg SN, Ahmed M. Thermal ablation therapy for hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:231S–244S.
Dupuy DE and Goldberg SH. Image guided radiofrequency ablation: challenges and opportunities. J Vasc Interv Radiol 2001;12:1135–1148.
Livraghi T, Goldberg SN, Monti F, et al. Saline-enhanced radiofrequency tissue ablation in the treatment of hepatic metastases. Radiology 1997;202:205–210.
Goldberg SN, Hanh PF, Halpern E, et al. Radiofrequency tissue ablation: effect of pharmacologic modulation of blood flow on coagulation diameter. Radiology 1998;209:761–769.
Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radiofrequency ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000;217:119–126.
Goldberg SN, Girnun G, Lukyanov AN, et al. Percutaneous tumor ablation: increased necrosis with combined radiofrequency and intravenous doxorubicin in a liposome carrier in a rat breast tumor model. Radiology 2002;222:797–804.
Goldberg SN, Kamel IR, Kruskal JB, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. Am J Roentgenol 2002:179:93–101.
Chopra S, Dodd GD, Chanin MP, Chintapalli KN. Radiofrequency ablation of hepatic tumors adjacent to the gallbladder: feasibility and safety. AJR Am J Roentgenol 2003;180:697–701.
Lu, DSK, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003;14:1267–1274.
Solbiati L, Ierace T, Goldberg SN, et al. Percutaneous US-guided radiofrequency ablation of liver metastases: treatment and follow-up in 16 patients. Radiology 1997;202:195–203.
Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radiofrequency ablation of hepatic metastases from colorectal cancer: long term results in 117 patients. Radiology 2001;221:159–166.
Gillams AR and Lees WR. Radiofrequency ablation of colorectal liver metastases in 167 patients. Eur Radiol 2002;14:2261–2267.
De Baere T, Risse O, Kouch V, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol 2003;181:695–700.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Brown, K. (2007). Percutaneous Radiofrequency Ablation in the Management of Patients With Colorectal Cancer. In: Markman, M., Saltz, L.B. (eds) Colorectal Cancer. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-215-1_11
Download citation
DOI: https://doi.org/10.1007/978-1-59745-215-1_11
Publisher Name: Humana Press
Print ISBN: 978-1-58829-751-8
Online ISBN: 978-1-59745-215-1
eBook Packages: MedicineMedicine (R0)